ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Biotechnology

Meiji Seika Pharma teams with lab to research hair loss cure

TOKYO -- Meiji Seika Pharma will partner with the government-affiliated Riken research institute to develop treatments to regrow lost hair, eyeing a full-fledged entry into the booming regenerative medicine field.

     The Meiji Holdings unit will work mainly with Takashi Tsuji, head of the Laboratory for Organ Regeneration at the Riken Center for Developmental Biology. Tsuji is known for using stem cells to regrow hair and teeth in mice. During the three-year partnership, Meiji Seika Pharma will test whether his research is applicable to humans and, if so, whether it can be commercialized.

     Riken will provide the necessary facilities, while Meiji Seika Pharma will furnish the funds. Should the research eventually lead to a marketable product, Meiji Seika Pharma plans to acquire a license from Riken to sell it.

     No cure exists for hair loss, which is believed to afflict more than 12 million adult men in Japan. Regenerative medicine is seen as a promising avenue for treatment.

     With conventional drugs becoming tougher to develop, pharmaceutical companies are increasingly turning to regenerative medicine. Japan has relaxed regulations in the field, requiring a shorter period of clinical testing than is needed for other medical products.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media